Testing pneumococcal vaccine during a fever in adults
Part of Infections clinical trials.
This trial tests if a pneumococcal vaccine (PCV-20) is safe and works well when given to adults during a fever. It may help protect people with certain health conditions from serious pneumococcal infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a fever of at least 100.4°F (38°C) at least twice recently
- You have a health condition like heart, lung, kidney, or liver disease, diabetes, or a weak immune system
- You are currently in the hospital for more than 24 hours
- You have never received a pneumococcal vaccine (PCV-7, PCV-13, or PCV-20) before
- You have not had a different pneumococcal vaccine (PPSV-23) in the past year
- You are not pregnant, breastfeeding, or on certain medications that weaken the immune system
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pneumonia vaccine (PCV13) in healthy infants to see if it works as well as a current vaccine. It compares the immune response and safety of the two vaccines.
This trial tests a new vaccine (called PCV26) in people 60 and older. The goal is to see if the vaccine is safe and to gather early information on how it works.
This trial tests a new 23-valent pneumococcal vaccine to see if it safely protects healthy people against pneumonia and other infections caused by pneumococcal bacteria.
This study tests a new pneumococcal vaccine (PCV15) to see how well it protects against carrying the bacteria that can cause pneumonia. Healthy adults aged 18–50 who have not had a pneumococcal vaccine in the last 5 years may join.
This trial tests a new pneumococcal vaccine (PCV24) in healthy infants and children. It aims to protect against serious infections like pneumonia and meningitis caused by pneumococcal bacteria.
This trial tests a catch-up pneumococcal vaccine for children and adolescents who may have missed some doses. It aims to see how safe and effective the vaccine is in healthy kids aged 15 months to 17 years.
Hear when a new Acute Febrile Illness trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.